Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 1, 2007, Pages 72-80

  Fan, Yue Zu ^a   Fu, Jin Ye ^b   Zhao, Ze Ming ^a   Chen, Chun Qiu ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^b People's Hospital of Pudong New Area   (China)

Author keywords

Apoptosis; Cell cycle; Gallbladder neoplasm; Growth; Norcantharidin; Proliferation; Proliferation and apoptosis related genes

Indexed keywords

BIOTIN; CYCLIN D1; CYCLINE; DNA; KI 67 ANTIGEN; MESSENGER RNA; NORCANTHARIDIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; STREPTAVIDIN; SURVIVIN; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL METABOLISM; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME CONDENSATION; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GALLBLADDER CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE; CELL PROLIFERATION; GALLBLADDER NEOPLASMS; HUMANS; TUMOR CELLS, CULTURED;

EID: 33846967813     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4:167-176.
2. Taner CB, Nagorney DM, Donobue HD. Surgical treatment of gallbladder cancer. J Gastrointestinal Surg 2004;8:83-89.
3. Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, Swanson RS, et al. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointestinal Surg 2004;8:183-190.
4. Muratore A, Polastri R, Capussotti L. Radical surgery for gallbladder cancer: current options. Eur J Surg Oncol 2000; 26:438-443.
5. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 2000;232:557-569.
6. Todoroki T. Chemotherapy for gallbladder carcinoma - a surgeon's perspective. Hepatogastroenterology 2000;47: 948-955.
7. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695.
8. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-1700.
9. Ishii H, Furuse J, Yonernoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 2004;66:138-142.
10. Kondo S, Nimura Y, Hayakawa N, Kamiya J, Nagino M, Uesaka K. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg 2000;87:418-422.
11. Houry S, Barrier A, Huguier M. Irradiation therapy for gallbladder carcinoma: recent advances. J Hepatobiliary Pancreat Surg 2001;8:518-524.
12. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the treatment of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002; 52:167-175.
13. Fan YZ, Fu JY, Zhao ZM, Chun CQ. Influence of norcantharidin on proliferation and apoptosis of GBC-SD cell lines of human gallbladder carcinoma. J Shanghai Med 2003;26(suppl):1-4.
14. Fan YZ, Fu JY, Zhao ZM, Chen CQ. The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism. Zhonghua Zhongliu Zazhi 2004;26:271-274.
15. Wang GS. Medical uses of Mylabris in ancient China and recent studies. J Ethnopharmacol 1989;26:147-162.
16. Liu J, Gao J, Liu X. Advances in the study of Cantharidin and its derivatives. Zhong Yao Cai 2003;26:453-455.
17. Williams LA, Moller W, Merisor E, Kraus W, Rosner H. In vitro anti-proliferation/cytotoxic activity of cantharidin (Spanish Fly) and related derivatives. West Indian Med J 2003;52:10-13.
18. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001;44:2065-2068.
19. McCluskey A, Ackland SP, Bowyer MC, Baldwin ML, Garner J, Walkom CC, et al. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003;31:68-79.
20. Mack P, Ha XF, Cheng LY. Efficacy of intra-arterial norcantharidin in suppressing tumor 14C-labelled glucose oxidative metabolism in rat Morris hepatoma. HPB Surg 1996;10:65-72.
21. Yang EB, Tang VVY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997; 117:93-98.
22. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991;15:883-886.
23. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol 2003;39:19-26.
24. Sun ZX, Ma QW, Zhao TD, Wei YL, Wang GS, Li JS. Apoptosis induced by norcantharidin in human tumor cells. World J Gastroenterology 2000;6:263-265.
25. Hong CY, Huang SC, Lin SK, Lee JJ, Chueh LL, Lee CH. Norcantharidin-induced post-G(2)/M apoptosis is dependent on wild-type p53 gene. Biochem Biophys Res Commun 2000;276:278-285.
26. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, et al. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002;100:158-165.
27. Chen YN, Cheng CC, Chen JC, Tsauer W, Hsu SL. Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 2003;140:461-470.
28. Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, et al. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 2002;128:223-230.
29. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur I Cancer 1995;31A:953-963.
30. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004; 14:1969-1973.
31. Baba Y, Hirukawa N, Tanohira N, Sodeoka M. Structure-based design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J Am Chem Soc 2003;125:9740-9749.
32. Matsuoka S, Yamaguchi M, Matsukage A. D-type cyclin-binding regions of proliferating cell nuclear antigen. J Biol Chem 1994;269:11030-11036.
33. Marx J. How cells cycle toward cancer. Science 1994;263:319.
34. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Diest Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 2000;156:585-594.
35. Hui AM, Li X, Shi YZ, Takayama T, Torzilli G, Makuuchi M. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res 2000;6:4272-4277.
36. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasm. J Pathol 1990;162:285-294.
37. Takasaki Y, Kogure T, Takeuchi K. Reactivity of anti-proliferating cell nuclear antigen (PCNA) murine monoclonal antibodies and human autoantibodies to the PCNA multiprotein complexes involved in cell proliferation. J Immunol 2001;166:4780-4787.
38. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation- associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
39. Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. Mod Pathol 2001;14:1008-1014
40. Hui AM, Li X, Shi YZ, Torzilli G, Takayama T, Makuuchi M. P27kip 1 expression in normal epithelia, precancerous lesion, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 2000;31:1068-1072.
41. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enlarged growth of mice lacking the cyclin-depcndent kinase inhibitor function of p27. Cell 1996;85:721-732.
42. Gillett CE, Smith P, Peters G, Lu X, Barnes DM. Cyclin-dependent kinase inhibitor p27 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. Pathology 1999;187:200-206.
43. Noguchi T, Kikuchi R, Ono K, Takeno S, Moriyama H, Uchida Y. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 2003;10:827-831.
44. Aoki T, Tsukinoki K, Karakida K, Ota Y, Otsuru M, Kaneko A. Expression of cyclooxygenase-2, BcI-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral Oncol 2004;40:954-959.
45. Qiu Z, Zhu J, Harms JS, Friedrichsen J, Splitter GA. Bovine herpesvirus VP22 induces apoptosis in neuroblastorna cells by upregulating the expression ratio of Bax to Bcl-2. Hum Gene Ther 2005;16:101-108.
46. Yu Z, Li W, Liu F. Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett 2004;215:159-166.
47. Zheng XL, Sun HX, Liu XL, Chen YX, Qian BC. Astilbic acid induced COLO 205 cell apoptosis by regulating Bcl-2 and Bax expression and activating caspase-3. Acta Pharmacol Sin 2004;25:1090-1095.
48. Bowen JM, Gibson Rj, Keefe DM, Cummins AG. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005;37: 56-62.
49. Tomazic A, Pegan V, Ferlan-Marolt K, Pleskovic A, Luzar B. Cyclin DI and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma. Hepatogastroenterology 2004;51:1832-1837.
50. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, et al. Prognostic value of Bax, Bd-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol 2005;58:159-165.
51. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, et al. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004;12:1189-1194.
52. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50:1986-1993.
53. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004;12:44-49.
54. Dai DJ, Lu CD, Lai RY, Guo JM, Meng H, Chen WS, et al. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol 2005;11:193-919.